Clinical trials: COPD Patients
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of PT003 compared with its individual components (PT001 and PT005), placebo and two active comparators to demonstrate superiority of the…
- Trial name
- NCT01085045
- Testing
- PT003 MDI, PT005 MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®)
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 118 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.
- Trial name
- NCT00949975
- Testing
- AZD9668
- Where
- 105 sites in United States, Australia and 10 more
- Volunteers
- 838 people
- Sponsor
- AstraZeneca
Stroke (CVA) or TIA, Diabetes
Risk Factors, Costs, and Impacts of ED Boarding
The goal of this observational study is to learn about the risk factors, costs, and operational impacts of emergency department boarding (patients admitted to the hospital but remaining in the emergency department awaiting…
- Conditions
- Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease)
- Trial name
- NCT07532564
- Where
- United States
- Volunteers
- 30,486 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
COPD, Dyspnea
Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients
Dyspnea is the most common symptom limiting the ability of COPD patients to perform activities of daily living. Although there has been research involving the benefit of providing Non Invasive Ventilation (NIV) during exercise to…
- Trial name
- NCT03349437
- Testing
- Vitabreath Device, Pursed Lip Breathing
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Philips Respironics
Pulmonary Disease, Chronic Obstructive
To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD
The primary objective of this study is to evaluate the effectiveness of TRELEGY ELLIPTA on health status in participants with symptomatic COPD.
- Trial name
- NCT05535972
- Testing
- FF/UMEC/VI
- Where
- China
- Volunteers
- 463 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)
The aim of the study is to compare the efficacy of roflumilast on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of salmeterol.
- Trial name
- EOS (NCT00313209)
- Testing
- Roflumilast
- Where
- 134 sites in Austria, Belgium and 8 more
- Volunteers
- 933 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This exploratory study will compare the efficacy of the fixed-dose combination (FDC) of aclidinium bromide and formoterol fumarate once daily in the morning and placebo once in the evening vs.
- Trial name
- NCT00706914
- Testing
- Once-daily aclidinium/formoterol, Twice-daily formoterol fumarate, Once-daily formoterol fumarate
- Where
- 40 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium
This study will assess the efficacy and safety of glycopyrronium bromide (NVA237) in patients with stable COPD, in comparison to an active comparator.
- Trial name
- NCT00501852
- Testing
- NVA237, Tiotropium
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
COPD
Dynamic Hyperinflation and Tiotropium
We will detect dynamic hyperinflation (DH) in 40 COPD (chronic obstructive pulmonary disease) patients with moderately severe disease using metronome paced hyperventilation (MPH) with inspiratory capacity as the primary end…
- Trial name
- NCT00569270
- Where
- 2 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Gelb, Arthur F., M.D.
Chronic Obstructive Pulmonary Disease
HFNC Effect on BCSS in Patients With COPD
The primary objective of this study is to look for a correlation between the use of high-flow nasal cannula in the outpatient setting in patients with previous chronic obstructive pulmonary disease exacerbation and the change in…
- Trial name
- COPD (NCT02825043)
- Testing
- High-Flow Nasal Cannula
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Oklahoma
Chronic Obstructive Pulmonary Disease (COPD)
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of the study is to compare the efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate and salmeterol/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT01908140
- Testing
- Aclidinium Bromide / Formoterol Fumarate, Salmeterol / Fluticasone
- Where
- 126 sites in Austria, Bulgaria and 12 more
- Volunteers
- 933 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan
The purpose of this study is to evaluate the safety and efficacy of Symbicort Turbuhaler compared to standard COPD treatment during one year in Japanese patients with COPD.
- Trial name
- NCT01070784
- Testing
- Symbicort Turbuhaler (Budesonide/formoterol), Drug: any available COPD treatment; investigator to decide
- Where
- 17 sites in Japan
- Volunteers
- 328 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice
The purpose of this study is to monitor the change in the health status of severe COPD patients after the initiation of Tiotropium therapy.
- Trial name
- NCT00624377
- Testing
- Tiotropium
- Where
- 17 sites in Taiwan
- Volunteers
- 2,031 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444.
- Trial name
- COPD (NCT01323660)
- Testing
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 307 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the onset of action of indacaterol (150 and 300 µg) as compared to placebo, salbutamol 200 µg and salmeterol/fluticasone 50/500 µg
- Trial name
- NCT00669617
- Testing
- Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg)
- Where
- 17 sites in United States, Belgium and 2 more
- Volunteers
- 89 people
- Sponsor
- Novartis
COPD
Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients
This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual…
- Trial name
- AVANT (NCT03022097)
- Testing
- Aclidinium bromide/formoterol Fixed-Dose Combination, Aclidinium bromide, Formoterol Fumarate
- Where
- 74 sites in China, India and 3 more
- Volunteers
- 1,625 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers
About 1 million individuals in the US have a prescription for supplemental oxygen (O2). Using O2 can prolong life and increase quality of life.
- Trial name
- PELICAN (NCT02098369)
- Testing
- Written education material (basic), Additional education material, PELICAN-Proactive
- Where
- 6 sites in United States
- Volunteers
- 444 people
- Sponsor
- University of Illinois Chicago
COPD Asthma
Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)
The purpose of this study is to evaluate the use of spirometry in identifying Diagnostic Error in COPD and Asthma patients.
- Trial name
- REDEFINE (NCT03137303)
- Testing
- Spirometry at initial visit, Albuterol, Spirometry at 12-month follow-up
- Where
- 2 sites in United States
- Volunteers
- 402 people
- Sponsor
- University of Illinois Chicago
Chronic Obstructive Pulmonary Disease (COPD
Adherence Study in COPD Patients
A randomized clinical study to assess the impact of Symbicort® pMDI medication reminders on adherence in COPD patients
- Trial name
- NCT02864342
- Testing
- Arm 1: BreatheMate device with application, Arm 2: BreatheMate device without application
- Where
- 8 sites in United States
- Volunteers
- 138 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Japan Long-term Safety for Tiotropium Plus Olodaterol
The primary objective of this study is to assess the safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC and olodaterol (delivered by the RESPIMAT Inhaler) in Japanese patients with Chronic…
- Trial name
- NCT01536262
- Testing
- Tiotropium + Olodaterol, Respimat, Olodaterol
- Where
- 24 sites in Japan
- Volunteers
- 122 people
- Sponsor
- Boehringer Ingelheim